Amid thousands of pilots, predictions and promises about AI, three health leaders brought something valuable to the conversation: ethics and experience. Hal Wolf, FHIMSS, Isaac Kohane, MD, PhD, and Ran Balicer, MD, MPH, PhD, have spent decades thinking about how information, technology and balanced human judgment can improve people’s health. Each approach challenges from a unique vantage point.

I had the privilege of moderating their HIMSS “Views from the Top” conversation about recognizing value when selecting AI applications. The subject may sound technical. The conversation was warm, personal and reflective. At its heart was a very human question: How do we make certain these extraordinary new capabilities actually improve people’s health?

Three Must-Hear Voices

The people leading this conversation matter. AI in health does not need more prediction for prediction’s sake. It needs experienced leaders who understand how innovation moves from possibility to policy, from data to decisions, and from scientific discovery to patients’ lives and into health professionals’ decision-making.

Hal Wolf, FHIMSS, sees health from a global systems perspective. As President and CEO of HIMSS, the world’s largest professional society for health informatics, he works with health systems, technology leaders, governments and policymakers around the world. Under his leadership, HIMSS has forged agreements with governments and public institutions to strengthen digital use and the infrastructure needed to make health information accessible and actionable.

Those relationships give Wolf a view few people have. He sees innovation across institutions, borders and policy environments. He also understands that technology does not transform health simply because it exists. Progress depends on whether policy, infrastructure, information and people can align to put innovation to work.

Isaac Kohane, MD, PhD, has spent his career asking difficult questions at the intersection of medicine, science, computation, ethics and patient care. As Chair of Biomedical Informatics at Harvard Medical School, the physician-scientist has helped shape the field that many health leaders are now trying to understand at extraordinary speed. At the foundation of his medical training and perspectives is his training in pediatric endocrinology.

His questions matter as much as the answers. What assumptions are hidden inside these systems? What happens when we use powerful technology to automate practices that were flawed to begin with? How do we distinguish an impressive computational result from something that creates genuine clinical value? Dr. Kohane keeps the focus on consequences: What happens when technological capability outpaces human understanding?

Ran Balicer, MD, MPD, PhD, sees patterns and possibilities in health information and understands how to put them to work. At Clalit Health Services, he works within one of the world’s largest integrated health organizations, where longitudinal information across millions of people can reveal connections that might never be apparent during an individual clinical encounter.

For Dr. Balicer, accumulating data is not just about knowing more. It is recognizing risk sooner and turning information into insight that leads to informed action. That can mean preventing a hospitalization, identifying someone who needs attention or giving a health professional information that could improve or save a life.

That is what made their HIMSS conversation so valuable. Rather than predicting an AI-defined future, they explored what experience is already teaching us: How to evaluate innovation thoughtfully, translate information into action and ensure that greater technological capability advances the health of the people and communities we serve. Here are 10 takeaway lessons from their conversation to carry forward and apply in planning.

HIMSS 2026 “Views From the Top” conversation with Hal Wolf, FHIMSS, Isaac Kohane, MD, PhD, and Ran Balicer, MD, PhD, moderated by Gil Bashe.

1. AI Is Already Here

Health organizations may still be debating their formal AI strategies while clinicians, employees and patients are already “vigilantes” using the technology. Dr. Kohane captured the tension well: Health systems can move too slowly and too quickly at the same time. Formal governance may proceed cautiously while people inside those same systems reach for readily available AI tools to solve problems in real time.

That changes the leadership question. It is no longer a question of whether AI will enter health.  That ship sailed long ago. The task is to understand how it is being used, where it adds value, where it creates risk and how leaders can guide its adoption responsibly.

2. Speed Still Needs Structure

Wolf has seen health technology move through transformational cycles before. When internet connectivity entered hospitals, clinicians wanted access before many institutions had built the infrastructure and security systems to support use at scale. People found workarounds because the need was pressing and governance had to catch up.

AI is moving much faster. The answer is not to freeze innovation until every question has been resolved. Health organizations need structures that allow people to move with greater confidence. Responsible governance should enable progress, not become another source of friction.

3. AI Requires Human Values

Dr. Balicer raised an idea that belongs in every room where an AI decision is being made: Algorithms contain opinions embedded in code. Every model reflects choices about what information matters, which outcomes are prioritized, what trade-offs are acceptable and how clinical success is defined.

We should worry about bias in data. We also need to look at the assumptions built into the technology itself. Selecting an AI system, therefore, requires more than asking whether it is accurate. Leaders need to understand whose priorities it reflects and whether those priorities align with the needs of health professionals, patients and public health systems.

4. Begin With the Problem

Anyone who walked the expansive HIMSS exhibit floor saw the investment companies are pouring into AI-supported technologies. The temptation is to begin with capability: Look what this can do. Wolf’s perspective points toward a better starting place: What health-system and patient-care problem are we trying to solve?

Health has accumulated decades of technology intended to create efficiency, sometimes producing another screen, another workflow, or another demand on a health professional’s time. AI cannot become the newest layer of complexity. Begin with the health problem, understand the outcome that matters and determine how success will be measured. Then decide whether AI can help.

5. Do Not Automate What Is Already Broken

Dr. Kohane offered one of the most memorable cautions of the conversation: AI could effectively pour concrete over some of the worst practices in medicine. That image stays with you because it captures the danger of assuming automation equals improvement.

A poorly designed workflow does not necessarily become better because it becomes faster. Misaligned incentives do not improve because intelligence is layered onto them. Fragmentation does not disappear because information moves more quickly. AI allows health to reconsider old processes rather than simply automate them.

6. Leaders Need to Get Their Hands Dirty

Dr. Kohane provided wonderfully practical counsel to executives: Use several AI models yourself. Ask them questions. Compare their responses. See where they agree and where they wander. Experience how remarkably confident an incorrect answer can sound.

Health leaders do not need to become computer scientists. They do need curiosity and enough direct experience to ask better questions. Leadership becomes difficult when our understanding of a transformative technology comes entirely through presentations, dashboards and other people’s interpretations.

7. Prediction Creates Responsibility

Dr. Balicer brought the conversation squarely into population health. AI increasingly allows health systems to identify people at risk before they arrive at a physician’s office. Imagine recognizing months earlier that someone may be headed toward hospitalization or a preventable complication. That is the promise health has discussed for decades: moving from reaction toward prevention.

The challenge arrives with the insight. What happens when a system identifies more people who could benefit from intervention than it has resources to help? Better prediction does not eliminate the challenges of access to care. It makes choices more visible. Knowing earlier also creates a responsibility to decide what we will do with that knowledge.

8. Give Time Back to Healers

Administrative AI matters. Reducing documentation burden, improving scheduling and making information easier to retrieve can return precious time to health professionals. The more important question is, how is that added time going to be used?  This is a critical decision that leaders and health professionals need to resolve.

If AI gives a physician another 30 minutes, does it create an opportunity to listen more closely to a patient, explain something more clearly or go home a little earlier after a difficult day?  Will institutions see this as an opportunity to schedule another two patient appointments? Does it reduce cognitive burden, or does the schedule simply absorb another appointment? The value of efficiency should ultimately be measured by what it gives back to people.

9. Move Beyond Pilots

The health system loves pilots. They let organizations explore, generate enthusiasm and manage risk. They can also become comfortable places to remain when the harder decision is determining what deserves to scale.

AI maturity requires choices. Which applications improve outcomes? Which reduce friction? What enables health professionals to make better decisions? Which secures wider trust? Which should be stopped? Pilots offer baseline experiential information. Progress comes when leaders are willing to act on what they learn and scale.

10. Technology Amplifies Our Choices

AI can find patterns that people might take months or years to see, summarize volumes of information that few clinicians have time to read and identify risk earlier than traditional systems allow. Those capabilities are extraordinary. They still cannot decide what kind of health system we want to create or when a diagnosis may overwhelm a patient who needs added time with a health professional.

That responsibility remains ours. Wolf’s experience reminds us that progress requires systems and policies capable of supporting innovation and the people within that institution. Dr. Kohane reminds us to question assumptions and subject technological capability to scientific and ethical scrutiny. Dr. Balicer shows what becomes possible when information is connected across populations and transformed into insight, enabling people to act sooner.

Their experience and perspectives do not provide every answer. They do something equally valuable by sharpening the questions health leaders must be asking. What problem are we solving? What evidence demonstrates value? What assumptions are embedded in the technology? Who benefits? Who might be overlooked? What will we do with the time, information and predictive capability AI returns to us?

These are leadership and governance questions more than technology questions. The conversation about AI in health is moving beyond whether machines can perform well at their tasks. We know they can (even with their false flags). Our opportunity is to connect that capability with human judgment and care, operational realities, and an understanding of the people we serve, whose lives depend on ethical and clinical decision-making.

Will AI Replace the Doctor?

That question is getting louder. Christina Farr recently brought Ezekiel (Zeke) Emanuel, MD, PhD, and John Whyte, MD, MPH, together on her podcast series, Lifers, to debate whether AI could replace physicians in significant areas of medicine by 2030.

Perhaps the more important question is not whether AI will replace health professionals. Wolfe and Drs. Kohane and Balicer offered a roadmap to explore that question: “It is what we should allow AI to replace, what we should insist it improve and what must remain fundamentally human.”

AI may eventually outperform people at an expanding number of clinical tasks. The measure of progress should be whether those capabilities improve health while giving health professionals greater capacity to do what people still need from people.

Technology will continue to become more informed. Our responsibility is to become wiser about how we use it, remembering that every data point ultimately represents a person counting on us to make the right choice.

The post 10 Things Health Leaders Need to Consider About AI Now appeared first on Medika Life.

Then eggs were declared acceptable again. Butter quietly returned to many breakfast tables. Researchers questioned whether whole milk was really worse than skim milk. Even the evidence surrounding red meat proved to be less certain than many people had assumed.

No wonder people throw up their hands and ask, “How can the experts keep changing their minds?”

The answer is actually reassuring. Science is supposed to change.

Yesterday’s certainty

When I was growing up, breakfast meant bacon, eggs, buttered toast, and a glass of whole milk. Few people questioned whether those foods were healthy.

Beginning in the 1960s, however, nutrition advice shifted dramatically. Saturated fat became the villain. We were encouraged to choose skim milk instead of whole milk, margarine instead of butter, and carbohydrates instead of fats. Red meat became something to limit. Eggs were viewed with suspicion. Millions of us faithfully changed our eating habits because we believed the science was settled. But science is rarely settled.

Looking more closely at the evidence

Over the past decade, researchers have reexamined many of the studies that shaped dietary recommendations. Several respected investigators concluded that the evidence supporting three daily servings of low-fat dairy was much weaker than most people realized. Likewise, convincing evidence that whole milk increases the risk of heart disease compared with reduced-fat milk has been difficult to demonstrate.

Researchers also questioned the assumption that whole-fat dairy inevitably promotes obesity. Some studies found just the opposite: because full-fat dairy is more satisfying, people may actually consume fewer total calories during the day.

And eggs got a reprieve on life a few years ago.

Red meat has generated similar debate. Several comprehensive reviews concluded that the evidence linking moderate red meat consumption with heart disease, cancer, or early death was less convincing than previously believed. These conclusions generated enormous controversy — not because researchers recommended eating more meat, but because they emphasized how uncertain the evidence actually was.

That distinction matters.

Nutrition studies are notoriously difficult to perform. Most rely on observing what people choose to eat over many years rather than randomly assigning thousands of people to follow a single diet for decades. Such observational studies can identify associations but cannot prove cause and effect.

That is why nutrition recommendations often evolve as new evidence accumulates.

What we know with greater confidence

Although individual foods continue to be debated, the overall picture has become much clearer. The healthiest diets around the world have remarkably similar characteristics. They emphasize vegetables, fruits, legumes, nuts, whole grains, and healthy oils. They include adequate protein from meat, fish, or high-proteinvegetables.

They minimize highly processed foods loaded with refined starches, added sugars, and excess sodium, what we now lump together as ultraprocessed foods. They avoid excessive calories.

Whether someone includes modest amounts of dairy or red meat appears to be far less important than the overall quality of the diet.

In other words, arguing over whole milk versus skim milk while drinking sugar-sweetened beverages and eating highly processed snack foods misses the bigger picture.

The real dietary villain

Perhaps the greatest nutritional lesson of the past several decades is that our attention was often directed toward the wrong target. We became preoccupied with individual nutrients — fat, cholesterol, carbohydrates — while the food environment around us changed dramatically.

Today’s supermarkets are filled with ultra-processed foods specifically engineered to be inexpensive, convenient, and difficult to resist. These products often contain combinations of refined flour, sugars, unhealthy fats, salt, and additives that encourage overeating. And they are cheaper relative to whole foods on a calorie for calorie basis, making them the choice of those with limited funds.

Meanwhile, consumption of vegetables, fruits, beans, nuts, and other minimally processed foods remains lower than recommended for most Americans.

That imbalance likely contributes far more to obesity, diabetes, and cardiovascular disease than whether someone occasionally enjoys a steak or drinks whole milk.

Humility is part of good science

One lesson extends beyond nutrition. Medicine constantly evolves. Here is a good example.

For many years physicians believed stomach ulcers resulted primarily from stress and excess stomach acid. Then two Australian physicians demonstrated that most ulcers were actually caused by the bacterium Helicobacter pylori. Their discovery transformed treatment and eventually earned them the Nobel Prize.

Progress occurred not because science failed, but because science corrected itself. Nutrition science works the same way. As better studies become available, recommendations should change. That is a strength, not a weakness.

So, what should we eat?

Fortunately, the answer is much simpler than many headlines suggest. Eat mostly real food. Fill your plate with vegetables and fruit. Choose beans, whole grains, nuts, seeds, and healthy oils, and first cold pressed extra virgin olive oil. Include fin fish often. If you enjoy dairy, modest amounts are fine, especially live culture unsweetened Greek yogurt. Eggs are healthy and poultry is a good protein source. If you enjoy red meat, have it occasionally rather than making it the centerpiece of every meal. The Mediterranean diet is essentially these choices.

Limit processed meats. Most importantly, avoid making ultra-processed foods the foundation of your diet.

Michael Pollan in his book In Defense of Food, summarized this approach beautifully: “Eat food. Not too much. Mostly plants.” That advice has aged remarkably well.

Another way to look at it

Instead of looking at one diet or another, a Harvard study published in 2025 analyzed what people actually ate in data from 30 years of the Nurses’ Health Study and the Health Professionals Followup Study. They asked the question: what did the people who lived to age 70 and were healthy in body and mind eat? Less than ten per cent of the 105,015 participants were alive and met that criterion at age 70. Here is what they ate during midlife. It turns out that they were eating mostly real foods with an emphasis on fruit, whole grains, vegetables with special attention to green leafies, more unsaturated than saturated fats, beans, soy products, yogurt, low-fat dairy, and berries. They tended to avoid trans-fats, processed meats, high-sodium foods, and sugary drinks. Sound familiar?

The authors concluded,“Our findings suggest that dietary patterns rich in plant-based foods, with moderate inclusion of healthy animal-based foods, may enhance overall healthy aging, guiding future dietary guidelines.

The bottom line

Nutrition headlines will continue to change. Future studies will challenge old assumptions, and some recommendations will inevitably be revised. But the fundamentals have remained surprisingly consistent.

The healthiest diet is not built around eliminating one food or glorifying another. It is built around balance, moderation, and eating foods as close as possible to how nature produced them. To carry it a bit further, “Don’t eat anything your grandmother would not recognize.”

Healthy aging is not built on finding the perfect food. It is built on consistently choosing better foods, staying physically active, maintaining a healthy weight, and letting good habits — not dietary fads — shape your future. This is what will assure you of many healthy years, a longer healthspan, not just lifespan.

Perhaps the greatest lesson is not that everything we once believed was wrong. It is that science is always learning — and so should we.

The post Nutrition Advice Keeps Changing — And What Never Changes appeared first on Medika Life.

Loneliness, it turns out, isn’t just an emotion. It’s a biological signal, as powerful and urgent as hunger or thirst. When you’re lonely, your brain doesn’t just feel sad. It sounds an alarm. Your body responds. And if that alarm keeps ringing, day after day, real physical damage begins.

Your Brain Treats Loneliness Like Starvation

Here’s something researchers at MIT discovered when they had people sit alone in a room for ten hours: afterward, when those isolated individuals looked at pictures of people laughing and connecting, the same part of their brain lit up that activates in people who are starving and looking at food. That’s not a metaphor. The craving for company and the craving for food share the same neural real estate.

Kay Tye, a neuroscientist at the Salk Institute for Biological Studies in California, has spent years mapping what she calls “social homeostasis” in the brain. Homeostasis is the fancy word for the way your body stays balanced. Your temperature stays near 98.6 degrees. Your blood sugar stays in a range. Tye’s research suggests that your need for human connection operates in the same way. Your brain has a set point. Stray too far from it, and systems start firing to bring you back.

In 2025, a paper published in Biological Psychiatry by Tye and colleagues formally introduced “social homeostasis” as a new way to think about mental health. The authors argue that chronic loneliness or overcrowding can shift the brain’s set point, leading to the kind of nervous system imbalance seen in many psychiatric conditions.

Deep Inside the Brain, a Social Thermostat

Catherine Dulac, a neuroscientist at Harvard University, wanted to know exactly where in the brain this social regulation lives. She looked to the hypothalamus, the ancient region buried deep in our skulls that controls hunger, thirst, and sleep. It turned out to be the right place to look.

In 2025, her team published findings from experiments on mice that had been separated from their companions for 5 days. They found two distinct clusters of neurons in the hypothalamus. One cluster fired when the animals were alone. The other fired when they were reunited. More telling: the longer the animals had been isolated, the more intensely they sought contact once reunion was possible. Greater deprivation, greater need. Just like thirst.

When researchers artificially activated the “separation” neurons, the mice actively avoided whatever chamber triggered the signal. Being alone felt bad, in a physical, measurable way. When they activated the “reunion” neurons, which connect to the brain’s dopamine reward system, the mice sought out that feeling. Connection felt good. Not just emotionally. Chemically.

These deep brain structures look nearly identical in mice and humans. We share this wiring because it’s ancient. The need to belong is not a modern luxury. It’s a survival code, written into the oldest parts of who we are.

Touch Matters More Than You Think

In Dulac’s experiments, vision didn’t count for much. Neither did sound or smell. Mice separated by a screen that still let them hear and smell each other reacted as if they were fully alone. The only sense that truly registered “I’m not alone” was touch. The physical presence of another body against their own.

Ishmail Abdus-Saboor, a neurobiologist at Columbia University, studies the specific nerve pathways dedicated to social touch in human skin. Our bodies actually have neurons in hairy skin that respond specifically to slow, gentle stroking, the kind a friend or family member might offer. These aren’t generic touch receptors. They’re wired for connection. A hug or a hand on the shoulder isn’t just a nice gesture. It’s information your nervous system uses to update its social score.

This is why phone calls help but don’t completely fill the gap. Why video chats feel better than nothing, but still leave something missing. Your brain needs data that only physical proximity can provide.

When Loneliness Goes Untreated, Your Body Pays

Social disconnection isn’t just hard on the heart emotionally. It’s hard on the actual heart. Research published in Cureus in 2025 reviewed data spanning decades and found that loneliness nearly doubles the risk of stroke and recurrent coronary artery disease, driven largely by increased inflammatory responses in the body.

The American Heart Association has stated that social isolation and loneliness raise the risk of heart attack, stroke, or death from either condition by about 30 percent. And a 2025 narrative review published in the journal Stress mapped the full internal chain of events: loneliness activates the body’s stress response system, raises cortisol levels, increases inflammatory proteins in the blood, changes how the amygdala reacts to social threat, and contributes to cardiometabolic risk markers.

Research published in Frontiers in Human Neuroscience in 2026 linked chronic loneliness to reduced gray matter in brain regions involved in memory and emotional regulation, including the hippocampus. It also found that loneliness is a significant risk factor for accelerated cognitive decline and dementia.

Put simply: isolation doesn’t just make us miserable. It changes our brain structure, disrupts our hormones, inflames our blood vessels, and shortens our lives.

What This Means for How We Live

Knowing that connection is a biological need rather than a preference changes the conversation. You’re not weak if you feel lonely. You’re not clingy if you crave company. You’re responding to an ancient alarm system that has kept our species alive for hundreds of thousands of years.

The research also offers a practical insight. Because touch plays such a central role, the quality of our physical presence with others matters enormously. Abdus-Saboor says he’s intentional about physical contact with his family every single day. Not grand gestures. Just a hug before the kids leave for school. A hand on a shoulder. A back rub. These aren’t small things. They’re medicine.

Tye adds another useful idea: building a variety of social settings into your life. Spending time alone, in small groups, and occasionally in larger groups can help your social thermostat stay flexible and resilient. The goal isn’t constant togetherness. It’s a healthy range.

It’s also worth noting that the damage from loneliness isn’t inevitable. Research on loneliness as a health issue consistently points to the same takeaway: these effects are modifiable. Community programs, social prescribing in healthcare, nature-based group activities, and intentional outreach to isolated neighbors all show measurable results.

The Bottom Line

If you feel lonely, don’t brush it off as a mood that’ll pass. Your brain is signaling something real. Your body is already responding. The good news is that connection, real physical presence with people who matter to you, works as powerfully in the other direction. It turns the alarm off. It restores the balance. It’s not a luxury. It’s what your biology has been asking for all along.

Science is saying what our hearts have always known: we need each other. Now we know exactly why.

The post Loneliness Is Not Just a Feeling. It’s a Biological Emergency appeared first on Medika Life.

Scientists have known about this problem for years and are now speaking up more openly. Most drugs that pass animal testing still fail once they are tried in humans. Different studies report different numbers, but many put the failure rate above 90 percent. That means for roughly every ten drugs that look promising and safe in a mouse or a rat, only about one will end up helping a real patient. Some researchers say that number gets used out of context, since animal testing is meant to catch problems early, not guarantee a drug will succeed. Nearly everyone in the field agrees the gap between animal results and human results is real, and it is large.

This isn’t a small technical detail. It means patients wait longer for treatments. It means research money gets spent chasing drugs that would never work in people. And for conditions like cancer, Alzheimer’s, and other brain diseases, it may be one reason so few genuine breakthroughs have reached the people who need them most.

Why a Mouse Body Isn’t a Human Body

The core issue is that animals and humans, while similar, are not the same. A disease that shows up in a mouse doesn’t always behave the way it does in a person. Sometimes it doesn’t show up in the animal at all.

Matthias Zilbauer, a doctor and researcher at the Cambridge Stem Cell Institute, put it plainly: “A lot of human diseases either do not occur in animals or occur in a different way because they’re not human. We want tests and models that can tell us which treatments work, and in what patients, and a mouse cannot tell us that.”

A recent study from Stanford looked closely at why dementia treatments that work well in mice keep failing in human trials. The researchers found that most mouse studies test a drug early, before any real signs of disease appear. Human trials almost always involve people who are already sick. Giving a drug to a healthy mouse before a disease starts is a very different test than giving that same drug to a person who already has memory loss or brain damage.

The study also found that most mouse research only used male mice, which means treatments that might work differently in women were never properly tested to begin with. In this sex bias, it is something that, in the past, has been endemic in research, with most results reflecting work with males, not females.

None of this means animal research is worthless. It has led to real, life-saving treatments for vaccines, cancer, and countless other conditions. But it also means animal results have limits that haven’t always been discussed honestly, and those limits matter most for diseases we still don’t know how to cure.

New Tools Built From Human Cells

Because of gaps like these, researchers in the UK are now building tools made directly from human tissue instead of relying only on animals.

In Cambridge, scientists are growing tiny clumps of human organs, called organoids, using cells donated by NHS patients. These clumps, some smaller than a millimeter, can mirror how an actual organ behaves, including how it responds to disease and to new drugs. Researchers are starting with organoids for bowel diseases like Crohn’s disease and ulcerative colitis, along with organoids to study tumors and brain conditions.

Other researchers are building “organ-on-a-chip” devices, small devices lined with real human cells that mimic how a drug moves through the body. One company, VivoSphere, is growing heart cells in small gel spheres to catch dangerous drugs before they ever reach an animal or a patient. As the company’s Yuan Tian explained, “If something is going to fail, there’s a lower risk for the animals and also for the patients.”

The UK government has backed this shift with money and deadlines. Under a new national roadmap, regulatory skin and eye irritation testing on animals is set to end by the close of 2026. Botox strength testing on mice is expected to end by 2027, replaced by lab-based methods that don’t require a live animal at all.

By 2030, the government wants to sharply cut testing on dogs and primates that tracks how drugs move through the body. In total, the UK has committed 75 million pounds to build out these new methods and make it easier for researchers to get them approved for use.

The United States is moving in a similar direction. In 2025, the FDA announced it would begin accepting artificial intelligence models, advanced lab-grown tissue tests, and other non-animal methods in place of some animal studies, starting with a pilot program for a class of drugs called monoclonal antibodies.

Why Animals Still Matter, and Why This Isn’t Simple

None of this means animal testing is about to disappear, and it would be unwise to suggest otherwise. Under UK law, animals cannot be used in research if a working non-animal method already exists to answer the same question. But for many questions, that alternative doesn’t exist yet.

Wendy Jarrett, who leads the group Understanding Animal Research, made this point clearly: animals have been fundamental to the discovery of most medicines available today, and to treating disease in people and animals alike. Edith Heard, director of the Francis Crick Institute, said much the same, noting that animal research remains necessary for complex diseases like cancer and Alzheimer’s, even as her institute works to reduce and replace it wherever possible.

This is also, importantly, a question of animal welfare, not just scientific accuracy. Last year in Britain alone, 2.54 million animal testing procedures were carried out, most involving mice, rats, fish, and birds. A small percentage involved dogs, cats, horses, and monkeys. Reducing that number matters on its own terms, separate from whether animal tests are scientifically reliable.

Groups on both sides, from the RSPCA to the pharmaceutical industry, have welcomed the UK’s new roadmap, which suggests this is one of the rare issues where scientists, drug companies, and animal welfare advocates largely agree on the direction, even if they disagree on how fast to move.

What seems to emerge is not a choice between animals and no animals, but a more honest reckoning with what animal testing can and cannot tell us. As Dr. Juliet Dukes of the charity Replacing Animals in Research put it, tools built from real human tissue have the potential to deliver something animal testing never could: medicine built around the actual patient in front of a doctor, not just the mouse in the lab down the hall.

The post Nine Out of Ten Cures Never Reach You appeared first on Medika Life.

Women never experience their health that way. Their lives do not fit neatly into funding categories, medical specialties or isolated episodes of care. Health is a continuum that shifts over time, and the market is finally beginning to recognize its size, scientific potential, and human importance.

A new W Group study, “The Road to the Era of Scale,” provides compelling evidence of that shift. Based on the organization’s tracking of more than 500 funding stories and approximately 164 disclosed equity rounds across 15 categories and more than 30 countries, the report found that women’s health companies raised a record $1.55 billion in disclosed equity in 2025, a 41% increase from 2024.

A Market Is Forming, Not Merely Making Headlines

Investment totals can be deceptive. One enormous financing round can make an entire sector appear stronger, deeper, and more expansive than it is in reality. The significance of the W Group findings is that the capital did not simply increase. It spread over the continuum of women’s health.

Eighty-five women’s health companies raised equity in 2025, the highest annual number in the report’s data. Ten rounds reached at least $50 million, twice as many as in 2024, and the average disclosed round grew 29%, from approximately $13.9 million to $18 million.

Capital also became less concentrated among a few celebrated companies. The three largest rounds represented 39% of disclosed funding in 2024, compared with 32% in 2025. Funding received by companies outside the top three grew by 56%, a potential signal that investors are beginning to support a broader range of clinical needs, technologies and business models.

This is what the development of an investment ecosystem looks like. Capital begins to flow beyond the familiar names and into diagnostics, therapeutics, clinical infrastructure and care models that address different stages of a woman’s life.

Oncology received the largest share of investment, with the report estimating more than $600 million across at least 12 rounds. Fertility and assisted reproductive technology attracted more than $230 million, while maternal health drew approximately $160 million. Menopause, sexual and reproductive health, hormone diagnostics and pelvic health also received new support.

Endometriosis offers a particularly important example. Long dismissed, misunderstood and frequently diagnosed only after years of pain, the condition attracted more than $56 million across five rounds in 2025. The investments spanned therapeutics, diagnostics, and imaging, suggesting that the market is beginning to view endometriosis as a complex clinical challenge requiring multiple forms of innovation.

The same shift can be seen in metabolic health. SheMed’s $50 million Series A helped establish women-specific GLP-1 care as an investable category, reflecting the growing recognition that medicines, monitoring and health interventions must account for biological differences rather than treating the male body as the universal clinical norm.

The Women’s Health Innovation Map Is Becoming Global

The United States remains the dominant destination for women’s health capital, but the sector is no longer exclusively an American story. The US ecosystem also benefits from Organon, one of the few global pharmaceutical companies built around women’s health, whose portfolio, partnerships and commercial reach can help promising science cross the difficult divide between startup innovation and patient access.

Beyond the United States, the report found a broader geographic footprint in 2025, with companies and investors across Europe, Israel, India, Canada and the Middle East contributing to the market’s development.

The UK was the most active non-US ecosystem by company count in the W Group data. British companies were represented across metabolic health, endometriosis, hormone diagnostics, menstrual health, maternal care and other categories.

That entrepreneurial activity is now being matched by policy attention. England published a renewed 10-year Women’s Health Strategy in April 2026, aligned with the country’s broader health plan and centered on giving women greater voice, choice and power in decisions about their care. The government has also outlined efforts to streamline gynecologic care, improve access for conditions such as endometriosis and fibroids and confront inadequate approaches to women’s pain.

This matters because innovation cannot succeed through capital alone. A company may develop a better diagnostic or care platform. Still, its impact will remain limited unless clinicians trust it, health systems can adopt it, reimbursement supports it and patients can reach it. That is the difference between invention and innovation.

France is building another part of that infrastructure. The Île-de-France region has created FemTech Île-de-France, an investment fund targeting €50 million for women’s health innovation, supported by the scientific expertise of Université Paris Cité. Regional plans also include a specialized incubator effort and an interdisciplinary institute that connects research, clinical education, and innovation.

The French initiative is notable because it does not treat funding as an isolated intervention. It attempts to link capital with scientific expertise, company development and a regional health innovation strategy. That combination can help promising startups move beyond an initial idea and toward evidence, regulatory progress and clinical adoption.

France’s women’s health momentum is also reflected in Lyon-based Ziwig Biotech, whose Endotest uses salivary RNA analysis and artificial intelligence to provide a noninvasive diagnostic test for endometriosis, demonstrating how French biotechnology can turn a condition long marked by diagnostic delay into a precision-medicine opportunity.

Israel contributes another important dimension. Its health innovation culture is built upon deep scientific expertise, sophisticated health data, globally connected medical centers and an instinct for solving difficult clinical problems. In 2025, Israel presented a delegation of women’s health innovators at Expo 2025 Osaka, bringing companies and health leaders together with counterparts from Japan, the United States and Mexico.

Israel’s strength in technology, however, coexists with a persistent capital and leadership gap for women. An Israel Innovation Authority report found that women remain approximately one-third of the country’s high-tech workforce, while holding only 17% of senior management positions and 10% of startup CEO roles. The number of women working in research and development has risen sharply, but their representation in entrepreneurship, leadership and investment remains disproportionately low.

That disparity should concern anyone interested in women’s health innovation. When women are missing from the rooms where companies are founded, clinical priorities are established and capital is allocated, unmet needs are more likely to remain unseen.

The opportunity in Israel has two paths to consider. The country can export women’s health technologies to global markets while also ensuring that more women participate as founders, scientific leaders, investors and decision-makers shaping those innovations.

The Most Dangerous Gap Sits in the Middle

The report’s most urgent finding is not the record amount invested. It is the continuing Series A bottleneck.

Approximately 35-40 women’s health companies raised seed or pre-seed capital in each of the two years studied. Only about 20 to 25 reached Series A, and many companies that appeared at the seed stage in 2024 did not return with a Series A round in 2025.

Seed funding can demonstrate that a concept is interesting. Series A funding is often the stage at which a company must demonstrate that the concept can become clinically credible, commercially sustainable, and capable of operating within a complex health system.

This stage requires companies to generate evidence, recruit specialized talent, navigate regulation, protect sensitive patient information and establish a credible path to payment. It is also where founders discover that a technically elegant solution may not fit naturally into clinical workflows or address the daily realities faced by patients and health professionals.

The loss of promising companies at this stage is not only a financial concern. A stalled financing round can mean that an earlier diagnostic never reaches a physician, a new treatment never enters a clinical trial or a more humane care model never reaches the people who need it.

Specialist funds can help bridge that gap, and the report identified at least 11 new investment vehicles launched in 2025 with a women’s health mandate. Pharmaceutical companies and major generalist venture firms are also beginning to participate, an important sign that the sector is moving beyond support from a small circle of committed specialists.

The transition remains incomplete. Women’s health will not achieve sustained growth until generalist investors consider it a standard component of health investing rather than a special theme to be visited only occasionally.

Capital Still Follows Visibility More Than Burden

The funding pattern also reveals an uncomfortable truth. Conditions receiving the most investment are not always those creating the greatest health burden.

The report estimates that women-specific cardiovascular innovation received only about $2 million in dedicated equity during 2025. Dedicated investment addressing the women-specific dimensions of autoimmune disease was effectively absent, even though women account for the great majority of people living with autoimmune conditions. Mental health and pelvic health also remained dramatically underfunded in relation to their effects on people’s lives.

This does not diminish the importance of investment in fertility, oncology, menopause or maternal health. It does show that markets often follow categories that are easier to describe, sell or recognize before addressing conditions that are scientifically complex, poorly diagnosed or fragmented across medical specialties.

Cardiovascular disease in women is not a niche concern. Autoimmune disease is not a specialty-market curiosity. These are major health challenges that demand gender-specific research, earlier diagnosis, appropriate clinical evidence and investors prepared to build a long-term thesis.

Five years ago, menopause appeared similarly overlooked. Greater visibility, advocacy and scientific attention helped change investor understanding. Cardiovascular, autoimmune, and mental health innovation now requires a comparable shift.

Scale Must Mean Better Health Access, Not Only Larger Rounds

Investment is essential, but capital is not the same as care. A successful financing announcement does not reduce the years a woman may wait for an endometriosis diagnosis, reduce the risk of maternal complications or ensure that a new technology reaches people regardless of income or geography.

The true value of capital lies in what it enables people to create. It can help researchers produce evidence, enable founders to recruit skilled R&D teams and give companies time to earn the confidence of regulators, health professionals, payers and patients.

Technology should simplify care rather than introduce another point of friction. Data should help clinicians understand women more fully rather than reproduce historical bias. Artificial intelligence, or its application, should enhance human judgment, not serve as an excuse for health professionals to distance themselves from the people they serve.

The women’s health sector no longer needs to prove that unmet need exists. The record of delayed diagnoses, inadequate research, and dismissed symptoms has been established many times over.

It also no longer needs to prove that successful companies can be created. The expansion of investment across more categories, countries and later-stage rounds shows that women’s health can produce significant scientific advances and scalable enterprises.

The question now is whether investors, policymakers and health systems will support those companies through the winding journey from possibility to practice. That will require patient capital, stronger evidence, workable reimbursement pathways, and a willingness to design care around women’s lives rather than forcing women to navigate systems not designed with them in mind.

The W Group Era of Scale analysis should not be measured only by how much capital enters women’s health. It should be measured by whether that investment leads to earlier diagnoses, better treatments, broader access and less suffering. The true measure of scale will not be dollars invested, but lives improved.

The post Women’s Health Has Entered the Era of Scale. Now Capital Must Catch Up With Care appeared first on Medika Life.

What Is Misophonia, Exactly?

The word misophonia comes from the Greek for “hatred of sound.” But that description sells it short. It isn’t simply an aversion to noise. It’s a disorder in which specific sounds, usually soft, repetitive, and made by another person, set off an intense chain reaction in the body and mind. Researchers define it as a condition characterized by strong emotional, physiological, and behavioral responses to sounds that most people barely notice.

The most common triggers include chewing, swallowing, lip smacking, slurping, throat clearing, sniffling, and breathing. Tapping on a keyboard, pen clicking, and the crinkle of a wrapper can also set it off. Some people also react to visual cues, such as watching someone’s jaw move, even without sound.

Estimates of how many people have misophonia vary, but multiple studies suggest that between 5% and 20% of the population experience symptoms significant enough to interfere with daily life. It often starts in childhood or early adolescence, with an average onset around age 12 to 13. It can persist for decades if left unaddressed.

What’s Happening in the Brain?

For a long time, people assumed this was a personality quirk or a sign of anxiety. New brain imaging research tells a very different story.

A landmark study published in Human Brain Mapping in early 2026 examined brain scans from 939 adults and found a specific connectivity disruption unique to misophonia. The culprit is a brain region called the anterior insula, a hub of the brain’s salience network. This is the area that decides, in a fraction of a second, what information deserves your full attention. In people with misophonia, the connection between the auditory cortex and the anterior insula is wired differently. The brain flags trigger sounds as urgent threats before the person has any chance to think about it.

Critically, this pattern did not appear in people with anxiety, depression, or autism, even when researchers analyzed the same brain data. It appears to be a misophonia-specific neural signature. That distinction matters enormously for treatment.

Earlier fMRI research confirmed that when a person with misophonia hears a trigger sound, specific regions fire up fast: the right insula, the anterior cingulate cortex, and the superior temporal cortex. Heart rate increases. Skin conductance rises. The emotional response arrives before reasoning can step in. This is why telling someone with misophonia to “just ignore it” is about as useful as telling someone with a broken leg to walk it off.

Research presented at the 2025 Misophonia Collaborative Forum added another dimension. Brain regions that become overactive during trigger exposure respond similarly whether a person is actually hearing the sound, watching a silent video of it, or simply imagining it. This tells us that misophonia isn’t purely a hearing problem. It involves memory, expectation, and mental imagery, too.

More Than Irritation: The Emotional and Physical Toll

The emotional range that people with misophonia report goes well beyond irritation. Anger is the most common reaction, but disgust, anxiety, panic, and even shame are also common. Physically, people describe muscle tension, sweating, nausea, a tightened chest, and a racing heart. The urge to flee the situation can feel overwhelming.

The source of the sound matters significantly. Research published in 2025 confirmed that sounds made by other people, especially people the listener knows, produce far stronger reactions than the same sounds made by strangers or machines. This is why family dinners can become unbearable war zones, while the same sounds in a crowded restaurant cause far less distress. It’s personal in the most literal neurological sense.

Research also finds that trigger sounds interfere with a person’s ability to concentrate on what they’re doing. People with misophonia are measurably worse at staying on task when triggers are present. Over time, the condition leads many people to avoid shared meals, open offices, public spaces, and sometimes their own families. The social and professional consequences can be severe.

Who Gets Misophonia?

Misophonia shows up across populations, but some groups appear more vulnerable. A 2025 systematic review found that between 12.8% and 35.5% of autistic people experience it, with 79% of those individuals also having anxiety, OCD, or other sensory sensitivities. It also appears frequently alongside mood disorders and obsessive-compulsive disorder in the general population.

Misophonia is not currently listed as a stand-alone diagnosis in the DSM-5 or ICD-11. But the field is moving toward formal recognition. In 2022, a consensus definition was published for the first time. Since then, standardized assessment tools have been developed, prevalence studies have grown in size and rigor, and clinical trials have finally begun.

What Can Actually Help?

Good news arrived in 2026 in the form of the field’s first randomized controlled trials, meaning research with a real comparison group and rigorous standards. Two studies confirmed that specific forms of therapy produce meaningful reductions in misophonia symptoms.

Cognitive behavioral therapy, or CBT, remains the most studied approach. A 2025 review presented at the World Tinnitus Congress confirmed that CBT delivered by both psychologists and audiologists significantly reduces the impact of misophonia on quality of life. Online CBT programs also show positive results, though dropout rates are higher than with face-to-face treatment.

Acceptance and commitment therapy, or ACT, also showed strong results in 2026 trials. ACT doesn’t try to eliminate the emotional response. Instead, it teaches people to tolerate distress without letting it control their behavior. For misophonia, this can mean staying at the dinner table, completing a workday in a shared office, or staying present in a relationship that might otherwise be derailed by triggers.

On the technology front, researchers at Duke University’s Center for Misophonia and Emotion Regulation are collaborating with a team at the University of Washington to develop a sound-suppression platform that uses headphones and an app. The goal is to allow a person to select which specific sounds they want filtered out while still hearing everything else.

Perhaps the most exciting frontier is neurostimulation. Clinical trials are underway to test whether transcranial magnetic stimulation, which uses magnetic pulses directed at specific brain regions, can calm the misfiring salience network at its source. If successful, this approach would be the first to directly target the underlying brain mechanism rather than managing its downstream effects.

You’re Not Alone, and You’re Not Broken

If any of this sounds familiar, the most important thing to know is that misophonia is real, it’s measurable, and it isn’t a personal failure. It also isn’t a life sentence. With the right support, people can and do find ways to manage their reactions, protect their relationships, and reclaim spaces that triggers have stolen from them.

Science has only recently begun to take misophonia seriously. The brain imaging findings of 2026 that show a disorder-specific neural signature are exactly the kind of evidence that turns skeptics into allies and moves conditions from the margins of medicine to its center. That shift is happening now.

Talk to a psychologist or psychiatrist who is familiar with sensory processing disorders. Be honest about what triggers you, how strongly, and how much it costs you in daily life. You deserve a professional who takes this seriously, because the science finally does.

The post That Sound Is Making Me Snap appeared first on Medika Life.

Its leaders were visible throughout the convention, participating in discussions on biopharma innovation, precision medicine, artificial intelligence, investment, genomics and policy. Partnership announcements emerged throughout the week. Delegations moved between panel discussions and private meetings with investors, entrepreneurs, researchers, and industry leaders. The message was clear. Abu Dhabi is making a strategic effort to become a notable player in biotechnology and the life sciences.

The timing is not accidental.

Around the world, governments increasingly view biotechnology as a strategic investment industry. Scientific innovation drives economic growth. Advanced therapeutics create new manufacturing opportunities. Genomics and precision medicine are reshaping approaches to disease prevention and treatment. Nations that attract talent, investment and scientific expertise position themselves at the forefront of one of the century’s most consequential industries and life-sustaining movements.

Abu Dhabi is determined to be among those countries.

Building the Innovation Foundation

Substantial investments and partnerships in infrastructure, research, education and health innovation support the Emirate’s ambitions.

In April 2025, Abu Dhabi launched the Health, Endurance, Longevity and Medicine (HELM) Cluster, an initiative designed to establish a globally competitive ecosystem spanning biotechnology, pharmaceuticals, medical technology, genomics, digital health, artificial intelligence and advanced manufacturing.

Officials project the initiative will contribute AED 94 billion to the economy by 2045, attract more than AED 42 billion in investment and create approximately 30,000 jobs.

Those figures reflect more than economic development goals. They signal a growing recognition that biotechnology is a cornerstone of future growth and global competitiveness.

The Emirate is not starting from scratch. Organizations including M42, PureHealth, Mubadala Bio, Khalifa University, and the Mohamed bin Zayed University of Artificial Intelligence have established a foundation that combines research, clinical capabilities, advanced analytics and investment resources. The UAE Genome Program has surpassed 900,000 sequenced genomes, making it one of the world’s largest population genomics initiatives and providing a valuable resource for scientific research and precision medicine.

These investments provide the ingredients necessary to compete. Partnerships provide the opportunity to accelerate progress.

Building Through Collaboration

Biotechnology has long been a collaborative enterprise among private equity and entrepreneurs, academic medicine and corporations, and, now, nations working side by side with other countries’ governments.

Scientific discovery depends on the exchange of knowledge among researchers, entrepreneurs, clinicians, manufacturers, regulators, and investors. No single country possesses every advantage. Successful ecosystems learn how to connect their strengths with those of others.

Abu Dhabi’s recent actions suggest its leaders understand this reality more than anyone else. They act on it.

During the BIO International Convention, the Department of Health – Abu Dhabi announced a strategic collaboration with Sanofi focused on vaccine development and life sciences innovation. The previous year at BIO in Boston, the Department established a partnership with Boehringer Ingelheim that expanded access to the company’s OpnME research platform, creating new opportunities for translational research and scientific discovery.

An additional 2025 agreement was signed with Abbott, focused on pharmaceutical innovation, manufacturing capabilities, and emerging technologies.

These were not isolated announcements. They represented a broader effort to connect Abu Dhabi with leaders across the global life sciences community. That strategy continued at BIO 2026.

On June 23, 2026, the Department of Health – Abu Dhabi announced a strategic partnership with Biocom California, one of the world’s largest life sciences associations representing more than 1,800 biotechnology, pharmaceutical, and medical technology organizations. The agreement creates a formal gateway between the California innovation ecosystem and Abu Dhabi’s growing life sciences sector, strengthening opportunities for collaboration among researchers, entrepreneurs, investors, and innovators across both markets.

The significance of the announcement extends beyond California. It reflects Abu Dhabi’s effort to connect itself to some of the world’s most influential innovation networks and to participate in the exchange of scientific knowledge, talent, and investment that increasingly defines biotechnology leadership.

Moving Up the Biotech Value Chain

If the Biocom agreement demonstrated Abu Dhabi’s commitment to global collaboration, a second announcement made the Emirate’s ambitions even clearer.

On June 24, 2026, the Department of Health – Abu Dhabi, M42, and Mammoth Biosciences announced a partnership to advance gene-editing therapies, clinical research, and advanced therapy manufacturing in Abu Dhabi. The agreement seeks to leverage insights generated through the Emirati Genome Program while supporting the development of next-generation treatments for inherited diseases.

This announcement stands out because it moves beyond ecosystem building and into the development of future therapies.

Mammoth Biosciences was co-founded by Nobel Prize-winning scientist Jennifer Doudna, whose pioneering work helped bring CRISPR gene-editing technology into medicine. Under the agreement, Mammoth will contribute its proprietary gene-editing platform, M42 will provide genomics, health, and clinical research infrastructure, and the Department of Health will support the regulatory and research environment needed to advance development.

The collaboration includes plans to introduce Mammoth’s lead clinical candidate, MB-111, into Abu Dhabi’s research ecosystem, support advanced gene-editing clinical trials, establish advanced therapy manufacturing capabilities, and develop local expertise through workforce training programs.

Perhaps most significantly, the partnership highlights how Abu Dhabi is leveraging its genomics investments. The Emirati Genome Program has created one of the world’s most comprehensive population genomics initiatives. The Mammoth agreement represents an effort to translate those insights into therapies targeting inherited diseases.

As H.E. Dr. Noura Al Ghaithi noted when announcing the partnership, Abu Dhabi is focused on translating genomic insights into therapies to address some of the most complex inherited diseases affecting populations in the region and worldwide.

Leadership Matters

The prominence of Abu Dhabi at BIO 2026 reflects sustained engagement from senior leaders. H.E. Dr. Noura Khamis Al Ghaithi, Undersecretary of the Department of Health – Abu Dhabi, and Dr. Mohamed Al Ameri, Division Director of Genome and Biobank at DoH, are among the officials representing the Emirate’s vision throughout the convention.

Their participation reflects a broader commitment. During Abu Dhabi’s 2025 strategic mission to the United States, approximately 40 representatives from 12 organizations attended more than 20 strategic meetings, conducted 16 institutional visits, participated in 9 BIO-related panels, and established 7 new partnerships and agreements.

Such activity underscores an important point. Building a biotechnology ecosystem requires more than investment capital. It requires leadership, patience, and a willingness to build relationships across borders and disciplines.

A Must-Watch Innovation Hub

For decades, discussions about biotechnology leadership have focused on a familiar collection of cities and regions. Boston, San Diego, Basel, London, and Singapore earned their positions through scientific excellence, entrepreneurial activity, and investment.

Abu Dhabi is pursuing a different path.

The Emirate is leveraging capital, scientific infrastructure, genomics, artificial intelligence, policy support, and international partnerships to establish a presence in the global biotechnology landscape. Its strategy recognizes that modern biotechnology advances through collaboration and that scientific leadership increasingly depends upon connecting talent, expertise, and resources across borders.

BIO 2026 demonstrated that Abu Dhabi is no longer simply expressing an ambition to participate in the life sciences sector. Through initiatives such as the HELM Cluster, partnerships with organizations including Sanofi, Boehringer Ingelheim, Abbott, Biocom California, and Mammoth Biosciences, and investments spanning genomics, research, and advanced therapies, the Emirate is laying the foundations for a biotechnology ecosystem with global aspirations.

Whether Abu Dhabi joins the ranks of the world’s leading life sciences hubs remains to be seen – but it should be watched closely. What is increasingly difficult to overlook is the depth of its commitment and the speed with which effort is being translated into action.

The post Abu Dhabi’s Biotechnology Ambition Comes into Focus at BIO 2026 appeared first on Medika Life.

Despite living longer than men, women spend approximately 25 percent more of their lives in poor health, according to research from the World Economic Forum and the McKinsey Health Institute. Across reproduction, brain health, autoimmune conditions, cardiovascular disease, and mental health, the gaps in research, funding, and care are persistent.

That reality provided important context for the launch of The Shift, a new mini documentary series from BBC StoryWorks Commercial Productions, unveiled at HLTH Europe. The series explores issues ranging from reproductive health and cardiovascular disease to autoimmune disorders, menopause, mental health and healthy aging. Through storytelling, the documentary project elevates the experiences of women while highlighting the challenges that persist and the opportunities for progress.

The HLTH EU panel discussion was timed for the opening of The Shift and featured Shahnoor Abbas, Senior Series Developer and Research Development Lead for The Shift at BBC StoryWorks Commercial Productions; Elena Bonfiglioli, General Manager, Global Health & Life Sciences at Microsoft, and Priya Agrawal, MD, Vice President, Global Health Equity and Partnerships at MSD. Their conversation, moderated by Jody Tropeano Greene, Head of Content for HLTH, explored why women’s health remains one of the most significant opportunities for innovation, investment and system improvement.

A Conversation Decades in the Making

The panelists approached the topic from different perspectives, yet a common theme emerged. Women’s health has received increasing attention for more than a decade, but many of the barriers women encounter remain rooted in the design of health systems.

For BBC StoryWorks, The Shift represents an effort to sustain attention on issues that too often receive episodic interest. The series combines personal stories with broader insights into the realities women face across different countries, cultures and stages of life.

The BBC initiative and the HLTH EU mainstage conversation arrive at a time when women’s health is attracting growing attention from investors, entrepreneurs, policymakers and health industry leaders. New companies are emerging. New technologies are being developed. More organizations are recognizing both the societal and economic importance of addressing longstanding gaps in care.

The timing of The Shift is notable. Women’s health innovation is receiving growing attention from investors, entrepreneurs, policymakers and health leaders. Industry analysts estimate that approximately $2 billion was invested in venture-backed women’s health companies across the United States and Europe in 2025, reflecting increased interest in addressing challenges that extend beyond reproductive health to include cardiovascular disease, menopause, mental health, oncology and healthy aging.

The trend signals growing recognition that improving women’s health is a societal imperative and a significant economic opportunity. Yet as the discussion at HLTH Europe made clear, investment and innovation alone will not be enough if women continue to face fragmented systems that are difficult to navigate.

When Access Exists but Navigation Fails

Dr. Agrawal, an obstetrician-gynecologist by training, whose work has included clinical practice in the UK NHS, global pharma brand stewardship in emerging middle-income nations, maternal health awareness initiatives, and the creation of sustainable health markets, described a reality familiar to many women. Access to care may exist on paper; however, reaching that care, understanding available options and navigating fragmented systems remains a challenge.

“We’ve built systems like mazes with different entry points, different providers and different messages,” said Dr. Agrawal. “Women are often left navigating all of this themselves at the moments where they are most vulnerable.”

Her observation echoed the comments by fellow panelists, which touched on an issue that extends beyond women’s health. Across many countries, patients frequently encounter disconnected providers, inconsistent communication and care journeys that require them to coordinate appointments, referrals and information on their own. The burden of connecting those pieces often falls on the individual seeking care rather than the system intended to support them.

For women, that complexity can be especially challenging. Responsibilities related to caregiving, work, family and personal health often intersect at the very moment care is needed. Understanding what symptoms are normal, knowing when to seek help, determining where to go and finding trusted sources of information become added obstacles.

That reality led to one of the discussion’s compelling observations. “This is not an access problem. It’s a design problem.”

The distinction matters. Discussions about women’s health often focus on whether services exist. Design asks a different question: can people realistically find, understand and benefit from those services when they need them most?

The Power of Stories to Sustain Change

The panel also explored the role technology may play in addressing those challenges. Rather than adding new layers of complexity, emerging digital tools and artificial intelligence applications are increasingly being developed to simplify navigation, improve continuity and support people between clinical encounters.

“What excites me is that technology is finally starting to reduce friction instead of adding layers of complexity,” Dr. Agrawal observed.

That perspective aligned with comments from Bonfiglioli, whose work at Microsoft focuses on helping health systems leverage data, cloud technologies and artificial intelligence to improve outcomes. Technology, however, was not presented as a solution on its own. The discussion repeatedly returned to the importance of human connection.

Those themes are central to the documentary series itself. BBC StoryWorks has built a reputation for transforming complex issues into compelling narratives that audiences can understand and relate to. Through The Shift, the goal is not merely to document challenges but to foster greater understanding of the experiences women face and the opportunities that exist to improve care.

Abbas emphasized the power of storytelling to connect data and lived experience. Statistics can identify a problem. Research can explain it. Stories help people understand why it matters and why action is necessary.

That may be the enduring value of The Shift. The series does not introduce a new conversation. Instead, it brings fresh perspectives to longstanding challenges. Through stories from around the world, the films remind viewers that behind every statistic is a person navigating the complexities of health and care. By fostering greater understanding and empathy, the series encourages health leaders, innovators and policymakers to view women’s health not as a periodic topic of interest, but as an ongoing priority deserving sustained attention and action.

The women featured throughout the series deserve more. The discussion at HLTH Europe reinforces that improving women’s health is more than developing new technologies and expanding services. It is also about creating systems that are easier to navigate, more responsive to people’s medical priorities and ultimately more human in their design.

The post At HLTH Europe, BBC StoryWorks Shines a Light on Women’s Health and the Challenge of Navigating Care appeared first on Medika Life.

Loneliness, it turns out, isn’t just an emotion. It’s a biological signal, as powerful and urgent as hunger or thirst. When you’re lonely, your brain doesn’t just feel sad. It sounds an alarm. Your body responds. And if that alarm keeps ringing, day after day, real physical damage begins.

Your Brain Treats Loneliness Like Starvation

Here’s something researchers at MIT discovered when they had people sit alone in a room for ten hours: afterward, when those isolated individuals looked at pictures of people laughing and connecting, the same part of their brain lit up that activates in people who are starving and looking at food. That’s not a metaphor. The craving for company and the craving for food share the same neural real estate.

Kay Tye, a neuroscientist at the Salk Institute for Biological Studies in California, has spent years mapping what she calls “social homeostasis” in the brain. Homeostasis is the fancy word for the way your body stays balanced. Your temperature stays near 98.6 degrees. Your blood sugar stays in a range. Tye’s research suggests that your need for human connection operates in the same way. Your brain has a set point. Stray too far from it, and systems start firing to bring you back.

In 2025, a paper published in Biological Psychiatry by Tye and colleagues formally introduced “social homeostasis” as a new way to think about mental health. The authors argue that chronic loneliness or overcrowding can shift the brain’s set point, leading to the kind of nervous system imbalance seen in many psychiatric conditions.

Deep Inside the Brain, a Social Thermostat

Catherine Dulac, a neuroscientist at Harvard University, wanted to know exactly where in the brain this social regulation lives. She looked to the hypothalamus, the ancient region buried deep in our skulls that controls hunger, thirst, and sleep. It turned out to be the right place to look.

In 2025, her team published findings from experiments on mice that had been separated from their companions for 5 days. They found two distinct clusters of neurons in the hypothalamus. One cluster fired when the animals were alone. The other fired when they were reunited. More telling: the longer the animals had been isolated, the more intensely they sought contact once reunion was possible. Greater deprivation, greater need. Just like thirst.

When researchers artificially activated the “separation” neurons, the mice actively avoided whatever chamber triggered the signal. Being alone felt bad, in a physical, measurable way. When they activated the “reunion” neurons, which connect to the brain’s dopamine reward system, the mice sought out that feeling. Connection felt good. Not just emotionally. Chemically.

These deep brain structures look nearly identical in mice and humans. We share this wiring because it’s ancient. The need to belong is not a modern luxury. It’s a survival code, written into the oldest parts of who we are.

Touch Matters More Than You Think

In Dulac’s experiments, vision didn’t count for much. Neither did sound or smell. Mice separated by a screen that still let them hear and smell each other reacted as if they were fully alone. The only sense that truly registered “I’m not alone” was touch. The physical presence of another body against their own.

Ishmail Abdus-Saboor, a neurobiologist at Columbia University, studies the specific nerve pathways dedicated to social touch in human skin. Our bodies actually have neurons in hairy skin that respond specifically to slow, gentle stroking, the kind a friend or family member might offer. These aren’t generic touch receptors. They’re wired for connection. A hug or a hand on the shoulder isn’t just a nice gesture. It’s information your nervous system uses to update its social score.

This is why phone calls help but don’t completely fill the gap. Why video chats feel better than nothing, but still leave something missing. Your brain needs data that only physical proximity can provide.

When Loneliness Goes Untreated, Your Body Pays

Social disconnection isn’t just hard on the heart emotionally. It’s hard on the actual heart. Research published in Cureus in 2025 reviewed data spanning decades and found that loneliness nearly doubles the risk of stroke and recurrent coronary artery disease, driven largely by increased inflammatory responses in the body.

The American Heart Association has stated that social isolation and loneliness raise the risk of heart attack, stroke, or death from either condition by about 30 percent. And a 2025 narrative review published in the journal Stress mapped the full internal chain of events: loneliness activates the body’s stress response system, raises cortisol levels, increases inflammatory proteins in the blood, changes how the amygdala reacts to social threat, and contributes to cardiometabolic risk markers.

Research published in Frontiers in Human Neuroscience in 2026 linked chronic loneliness to reduced gray matter in brain regions involved in memory and emotional regulation, including the hippocampus. It also found that loneliness is a significant risk factor for accelerated cognitive decline and dementia.

Put simply: isolation doesn’t just make us miserable. It changes our brain structure, disrupts our hormones, inflames our blood vessels, and shortens our lives.

What This Means for How We Live

Knowing that connection is a biological need rather than a preference changes the conversation. You’re not weak if you feel lonely. You’re not clingy if you crave company. You’re responding to an ancient alarm system that has kept our species alive for hundreds of thousands of years.

The research also offers a practical insight. Because touch plays such a central role, the quality of our physical presence with others matters enormously. Abdus-Saboor says he’s intentional about physical contact with his family every single day. Not grand gestures. Just a hug before the kids leave for school. A hand on a shoulder. A back rub. These aren’t small things. They’re medicine.

Tye adds another useful idea: building a variety of social settings into your life. Spending time alone, in small groups, and occasionally in larger groups can help your social thermostat stay flexible and resilient. The goal isn’t constant togetherness. It’s a healthy range.

It’s also worth noting that the damage from loneliness isn’t inevitable. Research on loneliness as a health issue consistently points to the same takeaway: these effects are modifiable. Community programs, social prescribing in healthcare, nature-based group activities, and intentional outreach to isolated neighbors all show measurable results.

The Bottom Line

If you feel lonely, don’t brush it off as a mood that’ll pass. Your brain is signaling something real. Your body is already responding. The good news is that connection, real physical presence with people who matter to you, works as powerfully in the other direction. It turns the alarm off. It restores the balance. It’s not a luxury. It’s what your biology has been asking for all along.

Science is saying what our hearts have always known: we need each other. Now we know exactly why.

The post Loneliness Is Not Just a Feeling. It’s a Biological Emergency appeared first on Medika Life.

A bill passed by the state legislature in March then signed into law by Democratic Gov. Jared Polis allows Colorado to further uncouple itself from federal guidance.

The law allows health officials to follow the recommendations of national medical groups when making decisions such as purchasing bulk vaccines for the Medicaid program.

“We are insulating our state from the dysfunction coming out of Washington,” said Democratic state Sen. Kyle Mullica, a co-sponsor of the bill and a registered nurse. “We’re going to rely on science.”

“From fighting during the pandemic for Coloradans to get vaccines as quickly as possible to combating the Trump Administration’s barriers to getting vaccinated, we have expanded access to vaccines for Coloradans who want them,” Polis said in a statement when he signed the law.

Colorado is one of at least 29 states that, along with Washington, D.C., have taken steps to bypass the new federal recommendations amid worries that the changes could chip away at public trust in vaccines and erode broad vaccine coverage.

Previously, Colorado, like most states, had followed federal guidance set by the Centers for Disease Control and Prevention. In January, CDC advisory panelists, selected by Health and Human Services Secretary Robert F. Kennedy Jr., removed six pediatric immunizations from the agency’s universal recommendation list.

Last year, doctors, scientists, local leaders, and other supporters came together to form an outreach and advocacy coalition called Colorado Chooses Vaccines.

The group aims to offer a clear, unified voice on the proven benefits of vaccines and reassure residents confused by the many federal changes.

Carol Boigon, a former Denver City Council member, joined the group because she wants more people to hear her own chilling story about vaccine-preventable illness.

“Every summer everybody got sick,” Boigon said, recounting her childhood in 1950s Detroit.

The illness was polio, a highly contagious viral disease that attacks the nervous system, sometimes causing partial or full paralysis.

During the summer of 1953, “the whole block was sick and some of us got crippled, and that was just the way it was,” she said.

New Group Steps Up

Boigon’s personal history will be part of the coalition’s work to educate new generations about the dangers of infectious diseases that were once common in the U.S. but are now relatively rare.

The group, which formed last September, will also compile vaccine information from medical groups and the state health department and advocate for policy proposals with the state government.

“It was in direct response to the federal threats,” said another coalition member, former state lawmaker Susan Lontine. She leads the nonprofit Immunize Colorado.

Another member, public relations specialist Elizabet Garcia, wants more outreach to Hispanics, whose vaccination rates lag behind other groups’.

“A lot of time it’s this fear that they’re going to have to pay out-of-pocket, that their insurance doesn’t cover it, that they might not even have insurance in general,” Garcia said.

Boigon was 5 when she got sick and was hospitalized for six weeks with a fever. The virus attacked her spine.

“None of my limbs worked immediately afterwards,” Boigon said.

Although she regained function in her other limbs, her right arm never fully recovered. She had to adapt, relearning everyday tasks such as reaching out to shake hands with people with her left hand.

In 1955, not long after she got sick, the new polio vaccine became more widely available to the public. As vaccinations took off, U.S. cases of polio, once one of the nation’s most feared diseases, dropped by an estimated 85%-90%.

Increasing Public Trust

State leaders have taken other steps to promote public health. After the Trump administration pulled the U.S. out of the World Health Organization, several states, including Colorado, decided to join the WHO’s Global Outbreak Alert and Response Network on their own.

Colorado also joined a multistate lawsuit challenging the Trump administration’s changes to the childhood vaccine schedule.

And the new state law has provisions besides allowing the state to diverge from federal recommendations. It codifies pharmacists’ ability to prescribe and give vaccines themselves. It also increases legal protections for healthcare workers who give vaccines.

“This law will provide more clarity to guide all Coloradans, including providers who administer vaccines,” Lontine said.

But the legislation has opponents who say it would interfere with parental choice and claim vaccines might be unsafe or ineffective.

“I just want to make sure we’re not just getting into a big political dispute between the federal recommendations — the CDC and so forth — and different political views in Colorado here,” said Republican state Sen. John Carson, who voted against the vaccine bill.

NPR contacted the U.S. Department of Health and Human Services about Colorado’s new law. Spokesperson Emily Hilliard answered in an email: “The updated CDC childhood schedule continues to protect children against serious diseases.”

Preventable Illnesses Surge

The flurry of statewide activity comes as Colorado and the nation have seen surges in illnesses such as flu and measles.

As of mid-May, Colorado had recorded 22 measles cases this year. In 2025, it registered 36 cases, according to the state health department, far surpassing totals from previous years.

Across Colorado, kindergarten vaccination rates for measles were 88% last school year — with only a few counties achieving rates of 95%, the level needed for herd immunity, according to data published by The Washington Post in December.

This has also been Colorado’s worst flu season in recent years.

Vaccination rates for both flu and covid-19 have dropped slightly in Colorado, according to the state health department.

Eight children in Colorado have died this season from flu; one from covid; and one from RSV, or respiratory syncytial virus. Vaccines for all three are available for children and recommended by the state’s health department.

Kennedy, a longtime anti-vaccine activist, has defended his decisions to overhaul the recommended schedule for childhood vaccinations.

In March, a federal judge put on hold many of the changes.

“We’re not taking vaccines away from anybody. If you want to get the vaccine, you could get it. It’s going to be fully covered by insurance just like it was before,” Kennedy told CBS News in January.

When a reporter suggested the new changes could result in fewer people getting a flu vaccine, Kennedy said: “Well, that may be, and maybe that’s a better thing.”

Boigon is sometimes incredulous at everything that has happened.

“It’s like we’re going backwards,” she said. “It’s like we have decided we don’t want a modern life; we want to be back in the 1950s, where children are sick and dying.”

This article is from a partnership with Colorado Public Radio and NPR.

The post Colorado Charts Its Own Course on Vaccines Amid Federal Pullback appeared first on Medika Life.